Schroder Investment Management Group Grows Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Schroder Investment Management Group raised its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 4.5% in the 4th quarter, Holdings Channel reports. The fund owned 77,715 shares of the medical research company’s stock after acquiring an additional 3,333 shares during the quarter. Schroder Investment Management Group’s holdings in IQVIA were worth $15,272,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in shares of IQVIA during the fourth quarter worth $336,041,000. Raymond James Financial Inc. acquired a new stake in shares of IQVIA in the 4th quarter worth $236,120,000. American Century Companies Inc. increased its stake in shares of IQVIA by 396.0% during the fourth quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company’s stock worth $222,987,000 after acquiring an additional 905,960 shares during the period. JPMorgan Chase & Co. raised its holdings in IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares in the last quarter. Finally, Nordea Investment Management AB lifted its position in IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after purchasing an additional 452,029 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on IQV. Robert W. Baird cut their target price on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research note on Tuesday, January 21st. Citigroup reduced their target price on IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Truist Financial reiterated a “buy” rating and issued a $263.00 price target (up previously from $261.00) on shares of IQVIA in a report on Monday, February 10th. Stifel Nicolaus decreased their price objective on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Finally, BTIG Research cut shares of IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Stock Down 3.9 %

IQV opened at $167.62 on Friday. The business’s fifty day simple moving average is $190.67 and its 200 day simple moving average is $204.66. IQVIA Holdings Inc. has a 52 week low of $166.11 and a 52 week high of $252.88. The firm has a market cap of $29.55 billion, a P/E ratio of 22.35, a PEG ratio of 1.99 and a beta of 1.50. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.